Results 41 to 50 of about 9,980 (152)

Antibiotic‐Impregnated Calcium Sulfate Beads for Local Therapy of Severe Skull Base Osteomyelitis

Clinical Case Reports, Volume 14, Issue 6, June 2026.
Novel Local Therapy of Severe Skull Base Osteomyelitis. ABSTRACT We report on a patient with severe progressive osteomyelitis of the lateral skull base, despite targeted long‐term antibiotic therapy. Successful treatment and recovery of the facial nerve palsy were achieved through additional surgical debridement and insertion of synthetic calcium ...
Stefan Lyutenski, Aviva Henze, Paul James, Marc Bloching   +3 more
wiley   +1 more source

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

mBio
β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an Escherichia coli clinical strain isolated from a patient who underwent ...
Akito Kawai, William C. Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L. Aitken, William C. Bachman, Christi L. McElheny, Micah M. Bhatti, Ryan K. Shields, Samuel A. Shelburne, Yohei Doi   +10 more
doaj   +1 more source

Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model [PDF]

Клиническая микробиология и антимикробная химиотерапия
Objective. To study pharmacodynamics of meropenem alone and in combination with avibactam in an in vitro dynamic model; to evaluate effectiveness of meropenem against K.
Strukova E.N., golikova-mv.
doaj   +1 more source

Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases

Biomolecules, 2020
Class D β-lactamases exhibit very heterogeneous hydrolysis activity spectra against the various types of clinically useful β-lactams. Similarly, and according to the available data, their sensitivities to inactivation by avibactam can vary by a
Jean-Marie Frère, Pierre Bogaerts, Te-Din Huang, Patrick Stefanic, Joël Moray, Fabrice Bouillenne, Alain Brans   +6 more
doaj   +1 more source

Emergence of Fosfomycin Resistance Among ESBL‐Producing Escherichia coli in Abadan, Southwestern Iran

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aim Escherichia coli is a key pathogen responsible for various infections, such as urinary tract infections, gastroenteritis, and wound infections. The increasing occurrence of antimicrobial resistance, particularly in extended‐spectrum β‐lactamase (ESBL)‐producing strains, poses a significant global health threat.
Nabi Jomehzadeh, Ali Fakari
wiley   +1 more source

The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower‐Middle‐Income Countries

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Digital databases such as pharmacovigilance (PV) databases could provide unique opportunities to monitor trends in suspected antibiotic resistance, ineffectiveness, and misuse, extending beyond their traditional role of tracking adverse drug reactions (ADRs).
Hager Saleh, Joseph Mitchell, Cecilia Stålsby Lundborg, Megha Sharma   +3 more
wiley   +1 more source

Guidelines for Essential Trauma Care: Second Edition (2026)

World Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock, Timothy C. Hardcastle, Christine Gaarder, Amit Gupta, Adam Gyedu, Manjul Joshipura, Elmin Steyn, on behalf of the Essential Trauma Care revision author group, Valencia Adjei, Roger Alcock, Vanda Amado, Michael Boampong, Sanjeev Booi, Petra Brysiewicz, Corazon Cabanilla‐Manuntag, Cristiane de Alencar Domingues, Ghada Elhadari, Ranjith Nanda Ellawala, Sarnai Erdene, Ama Akoma Essuman, Jorge Esteban Foianini, Filippo Gatti, Armando Garcia Guererra, Greg Hynes, Adil Haider, Sandy Ingless, Balavenkata Jagannathan, Helen Jowett, Knut Magne Kolstadbråten, Sonja Krofak, Aireen Patricia Madrid, Tina Tomić Mahečić, Claude Martin, Daniel Ntogwrachu, Bisola Onajin‐Obembe, Nhobojit Roy, Andres Rubiano, Niisoja Mensah Torto, Ben Wachira, Meg Walmsley, Torben Wisborg, Elma Wong   +41 more
wiley   +1 more source

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Microbiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck   +13 more
doaj   +1 more source

Effects of Nacubactam and Its Metabolites on QTc Interval: A Pooled Analysis of Two Randomized Phase 1 Studies

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley   +1 more source

Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System

Journal of Xenobiotics
Background: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj   +1 more source